Bhagiradha Chemicals & Industries delivered its highest-ever quarterly performance in Q1FY27, reporting a 235% year-on-year surge in net profit after tax (PAT) to ₹13.3 crore. The company’s revenue from operations climbed 58% to ₹195.0 crore, driven by robust volume growth, improved realizations, and a favorable product mix that included the launch of four new molecules in the mid- to high-value segments.

The filing, submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, was signed by Sharanya M., Company Secretary & Compliance Officer, on August 06, 2026. The presentation highlights a significant expansion in operating leverage, with EBITDA jumping 240% to ₹30.5 crore and gross profit rising 81% to ₹75.2 crore compared to Q1FY26.

Financial Highlights

The consolidated financial results for the quarter ended June 30, 2026, reflect strong margin expansion across key metrics:

Gross profit margin expanded to 38.6% from 33.5% in the previous year, while EBITDA margin more than doubled to 15.7% from 7.3%. The PAT margin also improved significantly to 6.8% from 3.2% in Q1FY26.

Operational Drivers

A. Arvind Kumar, Executive Director & CEO, attributed the growth to higher volumes and better realizations. The company introduced four new molecules—Tembotrione, Tolfenpyrad, Thifluzamide, and Novaluron—during the quarter, which contributed meaningfully to the growth trajectory. Raw material prices remained broadly stable, although select crude-linked inputs saw increases due to geopolitical developments in West Asia.

The Bheema Fine Chemicals facility continued its ramp-up, with capacity utilization nearly doubling compared to Q4FY26. This subsidiary remains focused on mid- and high-value molecules. At the existing Bhagiradha facility, management is gradually reducing the share of low-margin products and redeploying capacity toward higher-margin offerings to improve revenue quality.

What the Numbers Show

The disproportionate rise in EBITDA (240%) relative to revenue growth (58%) indicates substantial operating leverage gained through portfolio optimization. By shifting capacity away from low-margin products and leveraging the ramp-up at Bheema Fine Chemicals, Bhagiradha Chemicals has successfully decoupled margin expansion from pure volume growth, signaling a structural improvement in profitability drivers for FY27.

Bhagiradha Chemicals & Industries Limited reported a significant improvement in profitability for the quarter ended June 30, 2026, with consolidated net profit rising 29% year-on-year to ₹1,332.92 crore. The Hyderabad-based specialty chemicals manufacturer posted standalone net profit of ₹1,068.10 crore, up from ₹828.73 crore in Q1FY25, marking a substantial turnaround in earnings performance driven by robust demand in the chemical sector. This growth underscores the company’s ability to leverage operational efficiency amid rising top-line revenues.

The company’s Board of Directors, chaired by Managing Director S. Chandra Sekhar, approved the unaudited financial results on August 03, 2026, pursuant to Regulation 30 and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors. The newspaper advertisement was published on August 04, 2026, in Financial Express and Mana Telangana, as required for shareholder disclosure.

Financial Performance Highlights

Revenue from operations grew robustly, reflecting strong market conditions. Standalone revenue increased 38% year-on-year to ₹17,575.67 crore, while consolidated revenue rose 60% to ₹19,880.13 crore. This top-line expansion was accompanied by improved operational efficiency, leading to higher margins across both standalone and consolidated entities.

What the Numbers Show

The divergence between standalone and consolidated performance highlights the impact of subsidiaries on overall group profitability. While standalone PAT grew steadily, consolidated PAT saw a more dramatic increase, suggesting that associated companies or subsidiaries contributed disproportionately to the bottom line in Q1FY26. The equity share capital remained unchanged at ₹1,296.69 crore, indicating no new equity dilution during the period. Other equity reserves stood at ₹71,059.06 crore for standalone and ₹68,535.00 crore for consolidated operations as per the previous year’s audited balance sheet.